{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"}],"units":"Participants"}],"title":"Post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"groups":[{"description":"Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Atezolizumab + Bevacizumab - China"}],"paramType":"NUMBER","populationDescription":"The China ADA-evaluable population was defined as all participants in the China population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.","reportingStatus":"POSTED","timeFrame":"Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 18 months)","title":"Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}